BTG Pactual Global Asset Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

BTG Pactual Global Asset Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,204	Closed	-$1.74M	–	115
2020 Q4	$1.74M	Buy	+13,204	New	+$1.17M	0.24%	67

BTG Pactual Global Asset Management's EIDX Position: Q1 2021 in Review

BTG Pactual Global Asset Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 13,204 shares — an estimated $1.74M sold.

BTG Pactual Global Asset Management first reported a position in EIDX in Q4 2020 and held it in 1 quarter. The position peaked at $1.74M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

BTG Pactual Global Asset Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
BTG Pactual Global Asset Management sold 13,204 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.74M.
BTG Pactual Global Asset Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
BTG Pactual Global Asset Management's Eidos Therapeutics, Inc. Common Stock position peaked at $1.74M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on BTG Pactual Global Asset Management's 13F filing for Q1 2021, filed 14 May 2021.